You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma

Article info

Article menu

Download PDFPDF

XML
Short Report
CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma

Authors

  • Bryan D. Choi Cellular Immunotherapy Program, Cancer CenterMassachusetts General Hospital and Harvard Medical School 149 13th Street, Room 3.216, Charlestown 02129 Boston Massachusetts USA Department of NeurosurgeryMassachusetts General Hospital and Harvard Medical School Boston Massachusetts USA PubMed articlesGoogle scholar articles
  • Xiaoling Yu Cellular Immunotherapy Program, Cancer CenterMassachusetts General Hospital and Harvard Medical School 149 13th Street, Room 3.216, Charlestown 02129 Boston Massachusetts USA PubMed articlesGoogle scholar articles
  • Ana P. Castano Cellular Immunotherapy Program, Cancer CenterMassachusetts General Hospital and Harvard Medical School 149 13th Street, Room 3.216, Charlestown 02129 Boston Massachusetts USA PubMed articlesGoogle scholar articles
  • Henia Darr CRISPR Therapeutics Cambridge Massachusetts USA PubMed articlesGoogle scholar articles
  • Daniel B. Henderson CRISPR Therapeutics Cambridge Massachusetts USA PubMed articlesGoogle scholar articles
  • Amanda A. Bouffard Cellular Immunotherapy Program, Cancer CenterMassachusetts General Hospital and Harvard Medical School 149 13th Street, Room 3.216, Charlestown 02129 Boston Massachusetts USA PubMed articlesGoogle scholar articles
  • Rebecca C. Larson Cellular Immunotherapy Program, Cancer CenterMassachusetts General Hospital and Harvard Medical School 149 13th Street, Room 3.216, Charlestown 02129 Boston Massachusetts USA PubMed articlesGoogle scholar articles
  • Irene Scarfò Cellular Immunotherapy Program, Cancer CenterMassachusetts General Hospital and Harvard Medical School 149 13th Street, Room 3.216, Charlestown 02129 Boston Massachusetts USA PubMed articlesGoogle scholar articles
  • Stefanie R. Bailey Cellular Immunotherapy Program, Cancer CenterMassachusetts General Hospital and Harvard Medical School 149 13th Street, Room 3.216, Charlestown 02129 Boston Massachusetts USA PubMed articlesGoogle scholar articles
  • Genevieve M. Gerhard Cellular Immunotherapy Program, Cancer CenterMassachusetts General Hospital and Harvard Medical School 149 13th Street, Room 3.216, Charlestown 02129 Boston Massachusetts USA PubMed articlesGoogle scholar articles
  • Matthew J. Frigault Cellular Immunotherapy Program, Cancer CenterMassachusetts General Hospital and Harvard Medical School 149 13th Street, Room 3.216, Charlestown 02129 Boston Massachusetts USA Department of MedicineMassachusetts General Hospital and Harvard Medical School Boston Massachusetts USA PubMed articlesGoogle scholar articles
  • Mark B. Leick Cellular Immunotherapy Program, Cancer CenterMassachusetts General Hospital and Harvard Medical School 149 13th Street, Room 3.216, Charlestown 02129 Boston Massachusetts USA PubMed articlesGoogle scholar articles
  • Andrea Schmidts Cellular Immunotherapy Program, Cancer CenterMassachusetts General Hospital and Harvard Medical School 149 13th Street, Room 3.216, Charlestown 02129 Boston Massachusetts USA PubMed articlesGoogle scholar articles
  • Jason G. Sagert CRISPR Therapeutics Cambridge Massachusetts USA PubMed articlesGoogle scholar articles
  • William T. Curry Department of NeurosurgeryMassachusetts General Hospital and Harvard Medical School Boston Massachusetts USA PubMed articlesGoogle scholar articles
  • Bob S. Carter Department of NeurosurgeryMassachusetts General Hospital and Harvard Medical School Boston Massachusetts USA PubMed articlesGoogle scholar articles
  • Marcela V. Maus Cellular Immunotherapy Program, Cancer CenterMassachusetts General Hospital and Harvard Medical School 149 13th Street, Room 3.216, Charlestown 02129 Boston Massachusetts USA Department of MedicineMassachusetts General Hospital and Harvard Medical School Boston Massachusetts USA PubMed articlesGoogle scholar articles
  1. ↵q 617-726-5619 mvmaus{at}mgh.harvard.edu
View Full Text

Citation

Choi BD, Yu X, Castano AP, et al
CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma
Journal for ImmunoTherapy of Cancer 2019;7:304. doi: 10.1186/s40425-019-0806-7

Publication history

  • Received May 29, 2019
  • Accepted November 6, 2019
  • First published November 14, 2019.
Online issue publication 
January 08, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.